H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and set a price target of $45.00. The company's shares closed last Monday at $5.06, close to its 52-week low of $4.41. According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.1% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Checkpoint Therapeutics. Currently, the analyst consensus on Actinium Pharmaceuticals is a Moderate Buy with an average price target of $45.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-actinium-pharmaceuticals-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Actinium Pharmaceuticals Charts.
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Actinium Pharmaceuticals Charts.